Abstract
For a long time,in the context of depressive symptoms in schizophrenia traditional neuroleptics were mostly discussed with respect to possible depressiogenic side effects, although some studies argued that they may also have certain antidepressive effects. However, this was not proven at that time in placebo-controlled studies. Placebo-controlled studies performed in recent years have shown that second generation antipsychotics have antidepressive effects which are significantly stronger than those of the traditional neuroleptics. In addition, it was demonstrated that this antidepressive effect can only partially be explained as being secondary to the improvement of positive and negative symptoms, and is apparently predominantly due to a direct (primary) effect on depressive symptoms. It is of special relevance in this context that the antidepressive effect of second generation antipsychotics was recently demonstrated in depression. The positive results from some studies in bipolar depression are especially impressive and underline the antidepressive potencies of novel antipsychotics beyond the spectrum of schizophrenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adli M, Rossius W, Bauer M (1999) Olanzapine in the treatment of depressive disorders with psychotic symptoms. Nervenarzt 70:68–71
Amore M, Jori MC (2001) Faster response on amisulpride 50mg versus sertraline 50–100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 16:317–324
Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19:609–618
Banov MD, Zarate CA Jr, Tohen M, Scialabba D, Wines JD Jr, Kolbrener M, Kim JW, Cole JO (1994) Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 55:295–300
Bottlender R, Strauß A, Möller HJ (2000) Prevalence and background factors of depression in first admitted schizophrenic patients. Acta Psychiatr Scand 101:153–160
Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O (1999) Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology 39:25–32
Browne S, Garavan J, Gervin M, Roe M, Larkin C, O’Callaghan E (1998) Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 186:74–78
Calabrese J, MacFadden W, McCoy R, Minkwitz M, Wilson E, Mullen J (2004) Double-blind, placebo-controlled study of quetiapine in bipolar depression. Abstract presented at APA2004, NYC, USA
Cassano GB, Jori MC (2002) Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 17:27–32
Chacko RC, Hurley RA, Jankovic J (1993) Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 5:206–208
Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765–774
Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20:491–505
Dassa D, Kaladjian A, Azorin JM, Giudicelli S (1993) Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 163:822–824
De Alarcon R, Carney MW (1969) Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J 3:564–567
Dimova A (2003) The range of therapeutic efficacy of atypical antipsychotics: a critical evaluation. Med Hypotheses 61:259–264
Dube S, Paul S, Sanger T, Van Campen L, Corya S, Tollefson G (2002a) Olanzapine-fluoxetine combination in treatment-resistant depression. Eur Psychiatry 17(Suppl 1):98s
Dube S, Andersen SW, Paul S, Corya SA, Van Campen LE, Sanger TM, Welge L, Nanos J, Tollefson GD (2002b) Metaanalysis of olanzapine-fluoxetine use in treatment-resistant depression. Int J Neuropsychopharmacol 5(Suppl 1):S105
Dunner D, Amsterdam J, Shelton R, Hassman H, Rosenthal M, Romano S (2003) Adjunctive ziprasidone in treatment-resistant depression: A pilot study. Presented at the 156th APA Annual Meeting, San Francisco, CA, May 17–22, 2003
Emsley RA, Buckley P, Jones AM, Greenwood MR (2003) Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 17:210–215
Floru L, Heinrich K, Wittek F (1975) The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Long-term studies with fluspirilene and penfluridol and single-blind trial with fluphenazine-decanoate and flupenthixol-decanoate. Int Pharmacopsychiatry 10:230–239
Galdi J (1983) The causality of depression in schizophrenia. Br J Psychiatry 142:621–624
Galdi J, Rieder RO, Silber D, Bonato RR (1981) Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychol Med 11:713–728
Häfner H, Loffler W, Maurer K, Hambrecht M, an-der-Heiden W (1999) Depression,negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 100:105–118
Helmchen H, Hippius H (1967) Depressive Syndrome im Verlauf neuroleptischer Therapie. Nervenarzt 38:455–458
Hillert A, Maier W, Wetzel H, Benkert O (1992) Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome—a functional approach. Pharmacopsychiatry 25:213–217
Hirose S, Ashby CR Jr (2002) An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 63:733–736
Hirsch SR, Kissling W, Bauml J, Power A, O’Connor R (2002) A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 63:516–523
Jacobsen FM (1995) Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 56:423–429
Johnson DA (1981) Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr Scand 291(Suppl):137–144
Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6:325–337
Kay SR, Opler LA, Fiszbein A (1986) Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems Inc, North Tonawanda NY
Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePriest M (1995) Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 56:466–470
Keck PJ, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140:173–184
Knights A, Hirsch SR (1981) “Revealed” depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38:806–811
Lecrubier Y, Boyer P, Turjanski S, Rein W (1997) Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. J Affect Disord 43:95–103
Levinson DF, Umapathy C, Musthaq M (1999) Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 156:1138–1148
Marder SR, Davis JM, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538–546
McGlashan T, Carpenter WT (1976) Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 33:231–329
Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, et al. (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82–91
Meltzer HY, Okayli G (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152:183–190
Möller HJ (1990) Antidepressants and neuroleptics in treatment and prophylaxis of schizoaffective psychoses. In: Marneros A, Tsuang MT (eds) Affective and schizoaffective disorders. Berlin Heidelberg New York, Springer, pp 231–250
Möller HJ (2000 a) Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 1:75–91
Möller HJ (2000 b) State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 1:204–214
Möller HJ (2004) Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. Eur Arch Psychiatry Clin Neurosci (in press)
Möller HJ (2005) Antipsychotic and antidepressive effects of second generation antipsychotics—two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci (in press)
Möller HJ, Boyer P, Fleurot O, Rein W (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 132:396–401
Möller HJ, Follmann U, Scharl W, von Zerssen D (1985) Background variables of depressive states upon discharge of schizophrenic inpatients treated with neuroleptics. Pharmacopsychiatry 18:50–51
Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45–49
Möller HJ, von Zerssen D (1982) Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophr Bull 8:109–117
Möller HJ, von Zerssen D (1986) Depression in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G (eds) Handbook of studies on schizophrenia. Amsterdam Oxford New York, Elsevier, pp 183–191
Muller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O (2002) Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 22:554–560
Muller-Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O (1998) Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 18:111–120
Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl:54–59
Nelson EB, Rielage E, Welge JA, Keck Jr PE (2001) An open trial of olanzapine in the treatment of patients with psychotic depression. Ann Clin Psychiatry 13:147–151
O’Connor M, Silver H (1998) Adding risperidone to selective serotonin reputake inhibitor improves chronic depression. J Clin Psychopharmacol 18:89–91
Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256–259
Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M (2004) Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 65:217–221
Parker G, Malhi G (2001) Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry 35:631–638
Parsa MA, Ramirez LF, Loula EC, Meltzer HY (1991) Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 11:330–331
Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W (1999) Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 88:107–117
Peuskens J, Moller HJ, Puech A (2002) Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 12:305–310
Peuskens J, Van Baelen B, De Smedt C, Lemmens P (2000) Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15:343–349
Puech A, Fleurot O, Rein W (1998) Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 98:65–72
Ranjan R, Meltzer HY (1996) Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 40:253–258
Rapaport M, Canuso C, Loescher A, Lasser R, Gharabawi G (2003) Preliminary results from the ARISe-RD (Risperidone Augmentation in Resistant Depression) trial. Presented at the 156th APA Annual Meeting, San Francisco, CA, May 17–22, 2003
Rein W, Fleurot O, Turjanski S (1998) Amisulpride improves affective symptoms in acute schizophrenia. Eur Psychiatry 13 (Suppl 4):S309
Rifkin A, Quitkin F, Klein DF (1975) Akinesia: a poorly recognized drug-induced extrapyramidal disorder. Arch Gen Psychiatry 32:672–674
Rocca P, Fonzo V, Ravizza L, Rocca G, Scotta M, Zanalda E, Bogetto F (2002) A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 70:313–317
Rothschild AJ (2003) Challenges in the treatment of depression with psychotic features. Biol Psychiatry 53:680–690
Rothschild AJ, Bates KS, Boehringer KL, Syed A (1999) Olanzapine response in psychotic depression. J Clin Psychiatry 60:116–118
Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD (2004) A doubleblind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 24:365–373
Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY (1991) Clozapine treatment of psychiatric symptoms resistant to neuroleptictreatment in patients with Huntington’s chorea. Neurology 41:156
Schar V, Leonhardt M, Agelink A, Klieser E (1995) Risperidone in the treatment of patients with delusional depression. Pharmacopsychiatry 28:210
Schmidt AW, Lebel LA, Howard HR, Jr., Zorn SH (2001) Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197–201
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA et al. (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131–134
Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837–1847
Siris SG (2001) Suicide and schizophrenia. J Psychopharmacol 15:127–135
Siris SG, Bench C (2003) Depression and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Oxford, Blackwell Publishing, pp 142–167
Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142:430–436
Stoll AL, Haura G (2000) Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol 20:495–496
Thase ME (2002) What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 63:95–103
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW et al. (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079–1088
Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457–465
Tollefson GD, Sanger TM, Beasley CM, Tran PV (1998 a) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43:803–810
Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998b) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250–258
Van Putten T, May RP (1978) “Akinetic depression” in schizophrenia. Arch Gen Psychiatry 35:1101–1107
Vavrusova L (2002) Quetiapine in the treatment of non-psychotic depression. Int J Neuropsychopharmacol 5(Suppl 1):S104
Wassink TH, Flaum M, Nopoulos P, Andreasen NC (1999) Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 156:315–316
Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schroder J, Rein W, Benkert O (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology—a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137:223–232
Whitehead C, Moss S, Cardno A, Lewis G (2002) Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev: CD002305
Wood MJ, Rubinstein M (1990) An atypical responder to clozapine. Am J Psychiatry 147:369
Zarate CA, Jr., Rothschild A, Fletcher KE, Madrid A, Zapatel J (2000) Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 61:185–189
Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250–262
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Möller, HJ. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur Arch Psychiatry Clin Neurosci 255, 83–93 (2005). https://doi.org/10.1007/s00406-005-0580-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00406-005-0580-z